These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18204292)

  • 1. Beta-interferon protects multiple sclerosis patients against enhanced susceptibility to infections caused by poor air quality.
    Oikonen MK; Erälinna JP
    Neuroepidemiology; 2008; 30(1):13-9. PubMed ID: 18204292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis.
    Tremlett H; van der Mei IA; Pittas F; Blizzard L; Paley G; Mesaros D; Woodbaker R; Nunez M; Dwyer T; Taylor BV; Ponsonby AL
    Neuroepidemiology; 2008; 31(4):271-9. PubMed ID: 18971584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence.
    Oikonen M; Laaksonen M; Aalto V; Ilonen J; Salonen R; Erälinna JP; Panelius M; Salmi A
    Mult Scler; 2011 Jun; 17(6):672-80. PubMed ID: 21212088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ambient air quality and occurrence of multiple sclerosis relapse.
    Oikonen M; Laaksonen M; Laippala P; Oksaranta O; Lilius EM; Lindgren S; Rantio-Lehtimäki A; Anttinen A; Koski K; Erälinna JP
    Neuroepidemiology; 2003; 22(1):95-9. PubMed ID: 12566960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glypican 5 is an interferon-beta response gene: a replication study.
    Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
    Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis.
    Koch M; Mostert J; De Keyser J; Tremlett H; Filippini G
    Ann Neurol; 2008 Jan; 63(1):125-6; author reply 126-7. PubMed ID: 17702024
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.
    Farrell R; Kapoor R; Leary S; Rudge P; Thompson A; Miller D; Giovannoni G
    Mult Scler; 2008 Mar; 14(2):212-8. PubMed ID: 17986510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
    Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
    Farrell RA; Giovannoni G
    Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
    Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study.
    Mikaeloff Y; Caridade G; Tardieu M; Suissa S;
    Eur J Paediatr Neurol; 2008 May; 12(3):205-9. PubMed ID: 17881262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.